The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

The FDA accused Eli Lilly and Co. of “misleading” marketing, issued a formal warning letter, and asked them to stop publishing and distributing a brochure about the drug Alimta. If Lilly does not resolve the issue the FDA may decide to impose various penalties on the company. Federal officials reported that Lilly “omits material facts and risk information essential to the safe and effective use” of Alimta. Physicians prescribe this drug to treat mesothelioma and some forms of lung cancer.

Comments are closed.

Of Interest